(iv)
the possible treatment alternatives, including the follow-up measures if the participation of the subject in the clinical trial is discontinued;
← art_29__para_2__point_a__point_iii__text_1 · All articles · art_29__para_2__point_a__point_iv__text_1 →
Source: EUR-Lex (Cellar) · retrieved 2026-11-06 · Text as adopted (Official Journal); later amendments are not incorporated in this text.